Compounders Research Compare

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares(CUPR)

Medical - Instruments & Supplies · Singapore, CE

$2.11-0.14 (-6.22%)

Delayed quote: Oct 6, 2026, 11:48 AM EDT

About Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.

Singapore, CE

10 employees

www.cuprina.com.sg

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Yong Qi Quek

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T15:51:08.565Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:51:08.565Z.

Quote observation: 2026-10-06T15:48:44.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 5,657,438
Total debt · period ending 2025-12-31: 375,169.2068
Cash · period ending 2025-12-31: 2,423,062.4504
TTM free cash flow · period ending 2025-12-31: N/A

FMP input reference: 4cebeea1a9b4d788b134268ad244658713bcf5e38577c227b803d15950d20ec6

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CUPR EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

CUPR Competitors' EV/FCF Ratio

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

Current

Market Cap

$5.66M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lucyd, Inc

Market Cap

$5.85M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Acurx Pharmaceuticals, Inc.

Market Cap

$5.59M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Enlivex Therapeutics Ltd.

Market Cap

$5.94M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

enVVeno Medical Corporation

Market Cap

$5.84M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cardio Diagnostics Holdings, Inc.

Market Cap

$6.01M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Gelteq Limited Ordinary Shares

Market Cap

$5.14M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Alzamend Neuro Inc

Market Cap

$5.29M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Intelligent Bio Solutions Inc.

Market Cap

$5.25M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Pulmatrix, Inc.

Market Cap

$5.22M

EV/FCF Ratio

N/A

TTM Avg

1.32x

3Y Avg

1.32x

5Y Avg

1.32x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)	$5.66M	N/A	N/A	N/A	N/A
Lucyd, Inc (LUCY)vs ›	$5.85M	N/A	N/A	N/A	N/A
Acurx Pharmaceuticals, Inc. (ACXP)vs ›	$5.59M	N/A	N/A	N/A	N/A
Enlivex Therapeutics Ltd. (ENLV)vs ›	$5.94M	N/A	N/A	N/A	N/A
enVVeno Medical Corporation (NVNO)vs ›	$5.84M	N/A	N/A	N/A	N/A
Cardio Diagnostics Holdings, Inc. (CDIO)vs ›	$6.01M	N/A	N/A	N/A	N/A
Gelteq Limited Ordinary Shares (GELS)vs ›	$5.14M	N/A	N/A	N/A	N/A
Alzamend Neuro Inc (ALZN)vs ›	$5.29M	N/A	N/A	N/A	N/A
Intelligent Bio Solutions Inc. (INBS)vs ›	$5.25M	N/A	N/A	N/A	N/A
Pulmatrix, Inc. (PULM)vs ›	$5.22M	N/A	1.32x	1.32x	1.32x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics